Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

Abstract Background Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to reimbursement policies requiring patients to try multiple traditional pr...

Full description

Bibliographic Details
Main Authors: Ja Bin Hong, Kristin Sophie Lange, Mira Fitzek, Lucas Hendrik Overeem, Paul Triller, Anke Siebert, Uwe Reuter, Bianca Raffaelli
Format: Article
Language:English
Published: BMC 2023-10-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Preventive treatment
Monoclonal antibodies
Calcitonin gene-related peptide
Erenumab
Insurance coverage
Online Access:https://doi.org/10.1186/s10194-023-01682-2

Internet

https://doi.org/10.1186/s10194-023-01682-2

Similar Items